Drug Search Results
More Filters [+]

Eflornithine

Alternative Names: eflornithine, difluoromethylornithine, vaniqa, ornidyl
Latest Update: 2024-10-01
Latest Update Note: Clinical Trial Update

Product Description

Eflornithine administered by injection is used to treat African sleeping sickness, a disease caused by protozoa (tiny one-celled animals). However, eflornithine hydrochloride applied topically as a cream is the first agent known to help slow the rate of excessive hair growth. It is marketed under the brand name Vaniqa® and comes as eflornithine hydrochloride 13.9% cream. Eflornithine works by blocking the enzyme ornithine decarboxylase (ODC) that stimulates hair growth. (Sourced from: https://dermnetnz.org/topics/eflornithine-hydrochloride)

Mechanisms of Action: ODC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Latvia | Lebanon | Lithuania | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Slovakia | Spain | Sweden | Switzerland | Turkey | United Kingdom | United States

Approved Indications: None

Known Adverse Events: None

Company: Cancer Prevention
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eflornithine

Countries in Clinic: Honduras, Puerto Rico, United States

Active Clinical Trial Count: 6

Highest Development Phases

Phase 3: Astrocytoma

Phase 2: Brain Cancer|Carcinogenesis|Gastrointestinal Cancer|Glioma|Neuroblastoma|Osteosarcoma|Rhabdoid Tumor|Sarcoma, Ewing|Type 1 Diabetes

Phase 1: Glioblastoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BCC020

P2

Not yet recruiting

Glioma|Sarcoma, Ewing|Brain Cancer|Osteosarcoma|Neuroblastoma|Rhabdoid Tumor

2032-12-01

TADPOL

P2

Recruiting

Type 1 Diabetes

2027-12-01

OT-21-101

P1

Recruiting

Glioblastoma

2024-12-15

44%

STELLAR Study

P3

Active, not recruiting

Astrocytoma

2024-03-12

Recent News Events